Oncology
1845 CE — Case reports by John Hughes Bennett (Edinburgh) and Rudolf Virchow (Berlin), representing the first recognized clinical descriptions
Acute myeloid leukemia occupied a notably late place in the history of recognized diseases, as its identification depended entirely on the development of microscopy and the emerging science of cellular pathology in the nineteenth century. Before those technological advances, the condition was invisible to healers and physicians, its victims dying of causes that remained entirely mysterious. The unraveling of its nature unfolded rapidly once the tools to observe blood at the cellular level became available.
Historical Narrative
Because acute myeloid leukemia could not be distinguished from other causes of illness without microscopic examination of blood and bone marrow, no ancient or medieval record exists that can be confidently identified as describing the condition. Healers in ancient civilizations who encountered patients dying from what was likely this disease would have attributed the deaths to fevers, mysterious wasting, or imbalances of the humors — the four-fluid framework that dominated Western medicine from antiquity through the early modern period. There was simply no conceptual or observational framework within which such a blood-based malignancy could have been recognized.
The story of leukemia as a recognized entity began in the 1840s, when two physicians working independently reached strikingly similar conclusions almost simultaneously. John Hughes Bennett, a Scottish pathologist, published a case report in 1845 describing a patient whose blood appeared grossly abnormal, filled with what he called 'colorless corpuscles' in extraordinary numbers, and he attributed this finding to an inflammatory process he termed 'leucocythemia.' In the same year, Rudolf Virchow, the German pathologist who would become the dominant figure in cellular medicine in the nineteenth century, published his own observations of a similar case and used the term 'weisses Blut' — white blood — eventually settling on the Greek-derived 'leukemia' as the name for the condition. Virchow and Bennett engaged in a prolonged priority dispute, but Virchow's broader influence and his development of cellular pathology as a discipline meant that his framework came to shape how leukemia was understood.
Virchow went further in subsequent years to distinguish between different presentations of the disease, separating what he observed as a 'splenic' form from a 'lymphatic' form based on which organs appeared most affected, an early attempt at classification that laid the groundwork for later, more refined distinctions. The development of synthetic aniline dyes in the 1870s and 1880s transformed hematology by allowing pathologists to stain blood cells and differentiate their types with far greater precision. Paul Ehrlich applied these staining techniques extensively to blood analysis in the 1880s, enabling the identification of distinct cellular populations and advancing the ability to characterize leukemic blood more specifically.
By the late nineteenth century, pathologists had begun distinguishing between chronic and acute forms of leukemia based on the rapidity of the clinical course, and early in the twentieth century, Wilhelm Türk and others began describing the acute forms more precisely. The myeloid designation — reflecting an origin in the bone marrow and its progenitor cells — became more meaningful as understanding of hematopoiesis, the process by which blood cells are formed, matured through the early decades of the twentieth century.
The introduction of bone marrow biopsy and aspiration techniques in the early twentieth century, pioneered in part by the work of Moshe Sternberg and later refined by others, allowed for direct examination of the tissue where the malignant proliferation originated, transforming diagnosis from inference based on peripheral blood counts to direct observation of marrow architecture. By the mid-twentieth century, researchers including William Dameshek were working toward classification systems that distinguished the major leukemia subtypes, a project that culminated decades later in the French-American-British classification of 1976, which brought systematic order to the nomenclature and set the stage for the molecular era of understanding.
Key Historical Figures
Historical narrative only — this page describes how Acute myeloid leukemia was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.